Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: adenosine A3 antagonists - Future Medicine

Drug Profile

Research programme: adenosine A3 antagonists - Future Medicine

Alternative Names: A3AR antagonists - Future Medicine

Latest Information Update: 09 Mar 2018

At a glance

  • Originator Future Medicine
  • Class Antiasthmatics; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma; Middle East respiratory syndrome coronavirus; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal failure; Zika virus infection

Most Recent Events

  • 09 Mar 2018 Future Medicine has patent protection for adenosine A3 antagonists in South Korea, USA, Australia, China, India, Europe, Japan and Canada
  • 09 Mar 2018 Preclinical trials in Asthma in South Korea (unspecified route) before March 2018
  • 09 Mar 2018 Preclinical trials in Cancer in South Korea (unspecified route) before March 2018

Development Overview

Introduction

Future Medicines is developing nucleoside conjugate-based adenosine A3 antagonists, for the treatment of glaucoma, renal disorders, non-alcoholic fatty liver disease (NASH), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, middle east respiratory syndrome (MERS), Zika virus infections and cancer. Preclinical development is underway in South Korea.

One lead compound from the research programme, FM 101 [see Adis Insight Drug profile 800051460] is under preclinical development in South Korea, for the treatment of glaucoma.

Key Development Milestones

According to Future Medicine pipeline viewed in March 2018, preclinical development of adenosine A3 antagonists is underway for the treatment of glaucoma, renal disorders, non-alcoholic fatty liver disease (NASH), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, middle east respiratory syndrome (MERS), Zika virus infections and cancer (Future Medicine pipeline, March 2018).

Patent Information

Future Medicine has been granted a Korean patent (Registration No. 10-1 323 413) entitled "Pharmaceutical compositions for preventing or treating chronic diseases including (2R,3R,4S)-2-(2- chloro -6-(3-Idobenzylamino)-9H- Purine -9-il)-Tetrahydrothiophene-3,4- Diol and its derivatives" [1] .

The company has also been granted two Korean patents (Registration No. 10-1 192 097 and 10-1 181 627) entitled "Pharmaceutical composition comprising A3 adenosine receptor agonist for treating colon cancer", and "Pharmaceutical composition comprising A3 adenosine receptor agonist for treating prostate cancer", respectively.

A Korean patent has been granted to Future Medicine (Registration No. 10-1 067 604) entitled "Novel selenonucleoside derivatives or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the same as an active ingredient".

Future Medicine was granted several Korean patents (Registration No. 10-0 971 296; 10-1 251 282 and 10-1 709 307) entitled "4'-selenonucleoside derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and phrmaceutical composition for the prevention and treatment of cancers containing the same as an active ingredient", "Sulfonamide derivative which suppresses prostaclandin synthesis and a pharmaceutical composition containing the same", and "The pharmaceutical compositions for the prevention and treatment of the nash, liver fibrosis and liver cirrhosis containing adenosine derivatives", respectively.

In addition, the company has been granted an international patent [0 901 8371 (USA); ZL 200 780 052 031.X (China); 05 306 238 (Japan); 2 007 348 394 (Australia); 02 142 549 (4 European countries); 2 680 179 (Canada); 7220/CHENP/2008 (India)] entitled "Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention, and treatment of the inflammatory diseases containing, the same as an active ingredient".

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antiasthmatics, Antineoplastics, Antivirals, Eye disorder therapies, Hepatoprotectants, Nucleosides, Small molecules
  • Target Adenosine A3 receptor
  • Mechanism of Action Adenosine A3 receptor antagonists
  • WHO ATC code

    A05 (Bile and Liver Therapy)

    G04 (Urologicals)

    J05A-X (Other antivirals)

    L01 (Antineoplastic Agents)

    R03 (Drugs for Obstructive Airway Diseases)

    S01E-X (Other antiglaucoma preparations)

  • EPhMRA code

    A5 (Cholagogues and Hepatic Protectors)

    G4 (Urologicals)

    J5B9 (Antivirals, others)

    L1 (Antineoplastics)

    R3 (Anti-Asthma and COPD Products)

    S1E (Miotics and Antiglaucoma Preparations)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Asthma - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Cancer - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Chronic obstructive pulmonary disease - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Glaucoma - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Middle East respiratory syndrome coronavirus - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Non-alcoholic steatohepatitis - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Pulmonary fibrosis - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Renal failure - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018
Zika virus infection - - Preclinical South Korea unspecified / unspecified Future Medicine 09 Mar 2018

Commercial Information

Involved Organisations

Organisation Involvement Countries
Future Medicine Originator South-Korea
Future Medicine Owner South-Korea

Development History

Event Date Update Type Comment
09 Mar 2018 Patent Information Future Medicine has patent protection for adenosine A3 antagonists in South Korea, USA, Australia, China, India, Europe, Japan and Canada [1] Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Asthma in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Cancer in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Chronic obstructive pulmonary disease in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Glaucoma in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Middle East respiratory syndrome coronavirus in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Non-alcoholic steatohepatitis in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Pulmonary fibrosis in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Renal failure in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018
09 Mar 2018 Phase Change - Preclinical Preclinical trials in Zika virus infection in South Korea (unspecified route) before March 2018 Updated 09 Mar 2018

References

  1. Future Medicine - Patents. Internet-Doc 2018;.

    Available from: URL: http://www.futuremedicine.co.kr/en/about/property.html
Back to top